Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Doxycycline Shortage

 
The pages linked below are retained for archival purposes only and may not reflect current situations.
 

Tetracycline Shortage Update

The FDA reports the Tetracycline Shortage was resolved as of 3/17/2014

(July 31, 2014)

Doxycycline and Tetracycline Shortage Update

The U.S. Food and Drug Administration (FDA) placed doxycycline on the resolved drug shortage list as of October 23, 2013. 

Tetracycline is currently available in limited supply. For addition information regarding the drug availability of doxycycline and tetracycline, please see the FDA Drug Shortage Website at http://www.fda.gov/Drugs/drugsafety/DrugShortages/default.htm

(October 23, 2013)

Nationwide Shortage of Doxycycline: Resources for Providers and Recommendations for Patient Care - CDC Health Advisory, Health Alert Network (HAN)

(June 12, 2013)

Doxycycline and Tetracycline Shortage Update

The U.S. Food and Drug Administration (FDA) continues to report that doxycycline is available in limited supply and tetracycline is unavailable. If tetracycline or doxycycline is not available, other alternative regimens for young sexually active patients diagnosed with epididymitis are outlined below and described in the 2010 STD Treatment Guidelines. For additional recommendations and alternative regimens for syphilis in nonpregnant patients with a penicillin allergy, please contact a specialist or local health department.

(March 1, 2013)

Update: Tetracycline Shortage Notice

Update to the recently announced doxycycline shortage -- According to the U.S. Food and Drug Administration (FDA), tetracycline is currently unavailable. If tetracycline or doxycycline is not available, other alternative regimens for epididymitis and for syphilis in nonpregnant patients with a penicillin allergy are described in the 2010 STD Treatment Guidelines. For additional recommendations, please contact a specialist or local health department.

(February 8, 2013)

The Food and Drug Administration (FDA) reported a shortage of doxycycline on January 18, 2013. Doxycycline is a recommended therapy for some sexually transmitted infections and syndromes including chlamydia, nongonococcal urethritis, epididymitis and pelvic inflammatory disease. It is also an alternative therapy for syphilis in patients with a penicillin allergy. Doxycycline tablets/capsules are currently available in limited supplies. For additional information about the availability of doxycycline, visit the FDA Drug Shortage Website - http://www.fda.gov/Drugs/drugsafety/DrugShortages/default.htm. Other CDC recommended and additional alternative regimens are listed below and outlined in the 2010 STD Treatment Guidelines.

Chlamydia and Nongonococcal urethritis


Azithromycin 1 g orally in a single dose

Gonorrhea


Ceftriaxone 250 mg IM in a single dose

PLUS

Azithromycin 1 g orally in a single dose

Syphilis (penicillin allergic)


Primary or secondary syphilis

Tetracycline 500 mg orally four times daily for 14 days

Late latent syphilis

Tetracycline 500 mg orally four times daily for 28 days

Epididymitis


Ceftriaxone 250 mg IM in a single dose

PLUS

Azithromycin 1 g orally in a single dose

PLUS

Levofloxacin 500 mg orally once daily for 10 days

Pelvic Inflammatory Disease*


Ceftriaxone 250 mg IM in a single dose

PLUS

Clindamycin 450 mg orally four times daily for 14 days

WITH OR WITHOUT

Metronidazole 500 mg orally twice a day for 14 days


*see STD Treatment Guidelines for additional regimens

Top